Clinical Trial Update: A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial of BFB759 for moderate to severe hidradenitis suppurativa is currently recruiting, sponsored by Bluefin Biomedicine, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• BFB759

Snippet

Sponsor: Bluefin Biomedicine, Inc. | Conditions: Hidradenitis Suppurativa (HS) | Phase 2, Phase 3 | Status: RECRUITING